Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
| Tracking Information | |
|---|---|
| First Received Date ICMJE | January 4, 2011 |
| Last Updated Date | October 29, 2012 |
| Start Date ICMJE | January 2011 |
| Estimated Primary Completion Date | January 2013 (final data collection date for primary outcome measure) |
| Current Primary Outcome Measures ICMJE | Not Provided |
| Original Primary Outcome Measures ICMJE | Not Provided |
| Change History | Complete list of historical versions of study NCT01270399 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE | Not Provided |
| Original Secondary Outcome Measures ICMJE | Not Provided |
| Current Other Outcome Measures ICMJE | Not Provided |
| Original Other Outcome Measures ICMJE | Not Provided |
| Descriptive Information | |
| Brief Title ICMJE | Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer |
| Official Title ICMJE | Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer |
| Brief Summary | Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed. Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included). The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells. |
| Detailed Description | Not Provided |
| Study Type ICMJE | Observational |
| Study Design ICMJE | Observational Model: Case Control Time Perspective: Prospective |
| Target Follow-Up Duration | Not Provided |
| Biospecimen | Not Provided |
| Sampling Method | Non-Probability Sample |
| Study Population | lung tissue with primary malignant neoplasm |
| Condition ICMJE | The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined. |
| Intervention ICMJE | Not Provided |
| Study Group/Cohort (s) |
|
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Recruiting |
| Estimated Enrollment ICMJE | 20 |
| Estimated Completion Date | January 2013 |
| Estimated Primary Completion Date | January 2013 (final data collection date for primary outcome measure) |
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
| Gender | Both |
| Ages | 18 Years and older |
| Accepts Healthy Volunteers | No |
| Contacts ICMJE | Not Provided |
| Location Countries ICMJE | Israel |
| Administrative Information | |
| NCT Number ICMJE | NCT01270399 |
| Other Study ID Numbers ICMJE | MMC10160-2010CTIL |
| Has Data Monitoring Committee | No |
| Responsible Party | Meir Medical Center |
| Study Sponsor ICMJE | Meir Medical Center |
| Collaborators ICMJE | Not Provided |
| Investigators ICMJE | Not Provided |
| Information Provided By | Meir Medical Center |
| Verification Date | March 2012 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|